Obsidian Therapeutics Statistics
Want to see OBX full AI Analyst Report?
Obsidian Therapeutics (OBX) Stock Statistics & Valuation Metrics
Total Valuation
Obsidian Therapeutics has a market cap or net worth of $848.76M. The enterprise value is $148.50M.
- Market Cap
- $848.76M
- Enterprise Value
- $148.50M
Share Statistics
Obsidian Therapeutics has 61,772,877 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 61,772,877
- Owned by Insiders
- 98.80%
- Owned by Institutions
- 0.57%
Financial Efficiency
Obsidian Therapeutics’s return on equity (ROE) is 22.75 and return on invested capital (ROIC) is -92.23%.
- Return on Equity (ROE)
- 22.75
- Return on Assets (ROA)
- 20.71
- Return on Invested Capital (ROIC)
- -92.23%
- Return on Capital Employed (ROCE)
- -0.92
- Revenue Per Employee
- 0
- Profits Per Employee
- 1.71M
- Employee Count
- 87
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Obsidian Therapeutics is 0.05. Obsidian Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- 0.05
- PS Ratio
- 0.00
- PB Ratio
- 1.60
- Price to FCF
- -3.79
- Price to Operating Cash Flow
- -4.92
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Obsidian Therapeutics had revenue of 0 and earned 149.05M in profits. Earnings per share was 302.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -6.04M
- Pretax Income
- 149.05M
- Net Income
- 149.05M
- EBITDA
- -6.04M
- Earnings Per Share (EPS)
- 302.00
Cash Flow
In the last 12 months, operating cash flow was -1.63M and capital expenditures 0, giving a free cash flow of -1.63M billion.
- Operating Cash Flow
- -1.63M
- Free Cash Flow
- -1.63M
- Free Cash Flow per Share
- -3.31
Dividends & Yields
Obsidian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -46.43%
- Earnings Yield
- 1777.84%
Stock Price Statistics
- Beta
- 2.65
- 52-Week Price Change
- 174.04%
- 50-Day Moving Average
- 14.68
- 200-Day Moving Average
- 15.14
- Relative Strength Index (RSI)
- 46.79
- Average Volume (3m)
- 493.80K
Important Dates
Obsidian Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 18, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Obsidian Therapeutics as a current ratio of 11.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 11.00
- Quick Ratio
- 11.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.06
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Obsidian Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Obsidian Therapeutics EV to EBITDA ratio is -0.17, with an EV/FCF ratio of -0.32.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.17
- EV to Free Cash Flow
- -0.32
- EV to Operating Cash Flow
- -0.32
Balance Sheet
Obsidian Therapeutics has $5.50M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.50M billion.
- Cash & Marketable Securities
- $5.50M
- Total Debt
- $0.00
- Net Cash
- $5.50M
- Net Cash Per Share
- $0.09
- Tangible Book Value Per Share
- $10.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Obsidian Therapeutics is $39.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $39.33
- Price Target Upside
- 205.38% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- 48
